Journal of the Egyptian National Cancer Institute

Journal of the Egyptian National Cancer Institute is the official journal of the National Cancer Institute of Cairo University, and it publishes open access work on basic, applied and clinical cancer research from Egypt and further afield.《埃及国家癌症研究所杂志》是开罗大学国家癌症研究所的官方刊物，以开放获取方式发表来自埃及及更广范围的肿瘤学基础、应用与临床研究。

The 2025 journal citation report gives it an impact factor of 2.2 and a five-year figure of 2.4, placing the title in the third quartile of oncology within the emerging sources citation index.2025 年版期刊引证报告给出的影响因子为 2.2，五年影响因子为 2.4，该刊在新兴来源引文索引的肿瘤学类目居第三区。

Scope

• The journal welcomes submissions across all fields of cancer research, and it holds local and systemic anticancer therapy at the centre of its interest.该刊接纳肿瘤研究各领域的投稿，并把局部与全身抗肿瘤治疗置于关切的中心。

• A particular interest is taken in applied cancer research from the developing world, where the burden and the resources differ from those of richer settings.该刊对来自发展中国家的应用型肿瘤研究尤有兴趣，那里的疾病负担与资源同富裕地区不同。

• Experimental oncology is a named field, and laboratory work on the mechanisms of the disease is taken.实验肿瘤学是点名的领域，关于疾病机制的实验室工作得以收载。

• Early cancer detection is named as well, covering screening and the tests that precede a diagnosis.癌症的早期发现同样被点名，涵盖筛查以及诊断之前的各项检查。

• Randomized trials are welcome, and the journal states that negative trials are as acceptable as positive ones.随机试验受到欢迎，该刊声明阴性试验与阳性试验同样可以接受。

• Personalized medicine forms a further theme, and the journal follows molecular pathology in the service of treatment choice.个体化医疗构成又一个主题，该刊追踪服务于治疗选择的分子病理学。

• Bioinformatics is named among the emerging fields, and computational work on cancer data belongs to the scope.生物信息学列于新兴领域之中，面向肿瘤数据的计算工作属于其范围。

• Biotechnology applied to cancer is taken, covering the lab-based tools that reach the clinic.应用于肿瘤的生物技术得到收载，涵盖从实验室走向临床的手段。

• Surgical oncology, radiotherapy and nuclear medicine are all represented by papers in the journal's pages.外科肿瘤学、放射治疗与核医学都在该刊版面中有论文代表。

• Hematological malignancy is treated beside solid tumours, and work on leukaemia and on the blood-borne side of the disease is published.恶性血液病与实体瘤一并得到处理，关于白血病以及该病血液一面的工作都会发表。

• Pediatric oncology appears in the journal, and the Cairo institute's own pediatric service contributes to that strand.儿童肿瘤学出现在该刊之中，开罗该研究所自身的儿科部门也为这一方向供稿。

• Epidemiology and biostatistics are part of the scope, and a study may report the pattern of a cancer across a population.流行病学与生物统计学属于其范围，研究可以报告某种癌症在人群中的分布样态。

• Palliative and supportive care are within the remit, since the journal treats the patient rather than the tumour alone.姑息与支持治疗在其范围之内，因为该刊对待的是患者而非仅是一个肿瘤。

• The readership is clinical and academic, and the journal presents itself as a platform where academics and clinicians meet.读者为临床与学术两类，该刊把自身呈现为学界与临界面晤的平台。

History

• The journal was founded in 1982, and it has been issued by the National Cancer Institute of Cairo University ever since.该刊创办于 1982 年，此后一直由开罗大学国家癌症研究所发行。

• An earlier publisher line ran from Cairo, where the institute issued the title under the national imprint, before the journal moved to an open access platform abroad.较早的出版脉络起于开罗，研究所在此以国家级印本发行该刊，其后刊物迁往境外的开放获取平台。

• The medical library catalogue has covered the title since 2005, and it records coverage from volume 17 for both MEDLINE and PubMed.医学图书馆目录自 2005 年起收录该刊，其记载的 MEDLINE 与 PubMed 收录自第 17 卷开始。

• The journal later came to be published on the Springer open platform, under the imprint of BioMed Central in London.该刊后来改由 Springer 的开放平台出版，印本归属伦敦的 BioMed Central。

• The move carried the title into full open access, and the publisher states that it is free to publish in the journal.这次迁转把该刊带入完全开放获取，出版方声明在该刊发表不收费。

• Because no article processing charge is levied, the journal falls into the diamond class of open access, where the reader and the author both pay nothing.由于不收取文章处理费，该刊属于钻石类开放获取，读者与作者双方都无须付费。

• The gold share of its content stands at 100 per cent in the 2025 report, a figure that follows from the diamond arrangement.在 2025 年的报告中，其内容的金色开放获取比例为 100%，这一数字源于钻石模式。

• The journal has kept a quarterly rhythm, four issues to a volume, and its papers appear under the numbering of the journal on the platform.该刊保持季刊节律，一卷 4 期，其论文按平台上该刊的编号次序出现。

• The impact factor has moved from 2.1 in 2023 to 1.8 in 2024 and back to 2.2 in 2025, with a five-year value of 2.4.影响因子由 2023 年的 2.1 落到 2024 年的 1.8，再于 2025 年回升到 2.2，五年影响因子为 2.4。

• The journal gathers a steady body of work, some fifty papers a year, and it draws authors from across the region and beyond.该刊汇集的产出较为稳定，一年约五十篇论文，作者来自本地区及更远之地。

• The institute that owns the journal sits in Giza, and its staff supply a large share of the editors and, through its clinics, much of the material the journal reports.拥有该刊的研究所位于吉萨，其人员构成编辑的一大部分，并通过其门诊提供该刊所报道的大量素材。

Editors

• The editor-in-chief is Hussein Khaled of the Department of Medical Oncology at the National Cancer Institute of Cairo University.主编为开罗大学国家癌症研究所医学肿瘤学系的（Hussein Khaled）。

• A managing editor, Mohamed M. Sayed-Ahmed of the institute's cancer biology department, runs the day-to-day handling of manuscripts.执行编辑、研究所癌症生物学系的（Mohamed M. Sayed-Ahmed）负责稿件的日常处理。

• A large panel of associate editors stands behind them, drawn mainly from the Cairo institute but reaching into Saudi Arabia, Qatar, India and the United States.他们身后有一个庞大的副编辑团队，主要来自开罗该研究所，也延伸到沙特阿拉伯、卡塔尔、印度与美国。

• Among the associate editors are Hisham Abdel-Azim of Loma Linda University and Nagla Abdel Karim of the University of Virginia.副编辑中有洛马林达大学的（Hisham Abdel-Azim）与弗吉尼亚大学的（Nagla Abdel Karim）。

• Further associate editors sit at the All India Institute of Medical Sciences and at the King Hussein Cancer Center in Amman.另有副编辑任职于全印医学科学研究所与安曼的侯赛因国王癌症中心。

• An editorial board of some two dozen members is drawn in beside the associate editors, and it too is weighted towards the Cairo institute.除副编辑之外还纳入一个约二十余人的编委会，同样以开罗该研究所为主。

• Members of the board reach into France, Greece, Austria and Brazil, among them Etienne Brain of the Institut Curie and Nicholas Mottet of Saint-Etienne.编委延伸到法国、希腊、奥地利与巴西，其中有居里研究所的（Etienne Brain）与圣艾蒂安的（Nicholas Mottet）。

• Papers are peer reviewed, and the journal follows the publisher's editorial policies on ethics and disclosure.稿件经同行评议，该刊遵循出版方关于伦理与披露的编辑政策。

• Manuscripts are submitted through the publisher's online system, and the journal asks that a report of a trial give its design and its result without regard to whether the finding was positive.稿件经出版方的在线系统提交，该刊要求试验报告给出设计与结果，而不论发现是否为阳性。

• Authors are asked to state the ethical approval and the consent that underpin a clinical study, an expectation the journal shares with the wider medical press.作者被要求声明支撑一项临床研究的伦理批准与知情同意，这一要求是该刊与更广的医学出版界共同的。

• The journal takes review articles and original research together, so that a survey of a field and a single new result appear in the same pages.该刊把综述与原创研究并收，使一个领域的综述与单项新结果出现在同一版面。

• Imaging and pathology sit beside treatment in the pages, since a decision on therapy rests on what the images and the tissue show.影像与病理在版面中与治疗并列，因为治疗决策有赖于影像与组织所显示的内容。

• A paper may report a service improvement as well as a laboratory finding, and the journal treats the running of a cancer service as a fit subject.论文既可报告实验室发现，也可报告服务改进，该刊把肿瘤服务的运行当作合适的题材。

• Authors are asked to place their work in the context of the resources available where it was done, an emphasis the journal keeps for its regional readership.作者被要求把工作置于所在地可得资源的语境中，这一侧重是该刊为其地区读者所保持的。

• Work on cancer of the bladder, the liver and the breast appears alongside studies of leukaemia, reflecting the case load of the parent institute.关于膀胱、肝脏与乳腺肿瘤的工作与白血病研究一同出现，反映出母机构的病例积累。